FDA OKs NDA for SH-105 in Breast and Ovarian Cancer
The FDA accepted an NDA for SH-105, a ready-to-dilute treatment for breast or ovary adenocarcinoma, with a PDUFA target date of June 24, 2024. This formulation simplifies administration, improving efficiency and safety. Shorla Oncology also develops other cancer treatments, including SH-110 for glioma and SH-201 for various cancers, planning an NDA submission for SH-201 in Q1.
Reference News
The FDA accepted an NDA for SH-105, a ready-to-dilute treatment for breast or ovary adenocarcinoma, with a PDUFA target date of June 24, 2024. This formulation simplifies administration, improving efficiency and safety. Shorla Oncology also develops other cancer treatments, including SH-110 for glioma and SH-201 for various cancers, planning an NDA submission for SH-201 in Q1.